![Mark Vickery Mark Vickery](https://staticx.zacks.com/images/mugshots/mark_vickery/mark_vickery-8.png)
Top Stock Reports for Johnson & Johnson, Chevron & Adobe
![](https://staticx.zacks.com/images/zt/ztNow_icon2.png)
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thursday, June 6, 2019
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Chevron (CVX) and Adobe (ADBE). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Johnson & Johnson’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry so far this year (+4.1% vs. -0.1%). The Zacks analyst thinks J&J is likely to witness significant generic/biosimilar headwinds in the Pharma unit in 2019. However, J&J’s sales and earnings growth is expected to accelerate in 2020, supported by contribution from new drugs like Tremfya and successful label expansion of cancer drugs like Imbruvica and Darzalex and immunology drug, Stelara.
J&J is also making rapid progress with its pipeline and line extensions. It has already gained FDA approval for two new drugs in 2019, Balversa and Spravato. Meanwhile, share buybacks and restructuring initiatives should provide bottom-line support.
Headwinds like biosimilar/generic competition and pricing pressure remain. Allegations that its talc products contain asbestos, which causes users to develop ovarian cancer, continue to be an overhang on the stock.
(You can read the full research report on Johnson & Johnson here >>>).
Shares of Chevron have outperformed the Zacks Integrated Oil industry in the past six months (+1.8% vs. -1.9%). The Zacks analyst thinks Chevron’s financial results have greatly improved over the past few quarters, primarily aided by surging production and free cash flow turnaround. In fact, Chevron's free cash flow and upstream production for 2018 hit a record.
The company’s existing oil and gas development project pipeline is among the best in the industry, targeting a CAGR of 3-4% through 2023 thanks to the planned expansion in the Permian Basin. Moreover, growing free cash flow should enable Chevron to deliver stable and rising dividends in the foreseeable future. However, there are worries of a drop in its downstream earnings.
Meanwhile, Chevron's decision to walk away from the Anadarko transaction meant that the company lost the chance to significantly augment its substantial Permian holdings. Hence, investors are advised to wait for a better entry point.
(You can read the full research report on Chevron here >>>).
Adobe’s shares have gained +10.3% over the past year, underperforming the Zacks Software industry which has increased +20.5% over the same period. However, the Zacks analyst thinks Adobe is riding high on benefits gained from the Magento and Marketo acquisitions. Further, increasing demand for its creative products is driving top-line growth.
The company has been making great efforts toward establishing its presence in cloud-related areas such as documents and marketing. Adobe’s market position, compelling product lines, continued innovation, solid adoption of Creative Cloud and Adobe marketing cloud provides cause for optimism. Estimates have been stable ahead of the company’s Q2 earnings release.
The company has a mixed record of earnings surprises in recent quarters. However, lower end-market demand and exposure to Europe remain overhangs. Further, high acquisition expenses do not bode well for margin expansion.
(You can read the full research report on Adobe here >>>).
Other noteworthy reports we are featuring today include Boston Scientific (BSX), Las Vegas Sands (LVS) and Southern Copper (SCCO).
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Get the latest research report on CVX - FREE
Get the latest research report on BSX - FREE
Get the latest research report on JNJ - FREE
Get the latest research report on LVS - FREE
Get the latest research report on ADBE - FREE
Get the latest research report on SCCO - FREE